Tobacco use disorder and cardiovascular health

被引:55
作者
Benowitz, Neal L. [1 ,2 ]
Liakoni, Evangelia [3 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Cardiol, Clin Pharmacol Res Program, POB 1220, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA USA
[3] Univ Bern, Bern Univ Hosp, Inselspital, Dept Gen Internal Med,Clin Pharmacol & Toxicol, Bern, Switzerland
关键词
cardiovascular; cigarette; heart; nicotine; smoking; tobacco; PLACEBO-CONTROLLED TRIAL; SMOKING-CESSATION; SMOKELESS TOBACCO; CIGARETTE-SMOKING; MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE; RISK-FACTORS; COLLABORATIVE METAANALYSIS; ELECTRONIC CIGARETTES; POLICY STATEMENT;
D O I
10.1111/add.15703
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This narrative review examines the impact of cigarette smoking and the use of other tobacco and nicotine products on cardiovascular disease. Smoking increases the incidence of both acute and chronic cardiovascular diseases, and the harmful effects are substantially and relatively quickly reversible after quitting. Recommended cessation treatment includes offering pharmacotherapy, counseling which should emphasize the rapid risk reduction that occurs after quitting and adequate follow-up contacts. Although most research on cardiovascular disease in relation to tobacco use has focused upon cigarette smoking, we also review available data related to other combustible tobacco products, smokeless tobacco, electronic nicotine delivery systems and second-hand smoke. We discuss the implications of smoking on clinical management of patients with heart disease and newer developments with potential relevance to treatment of such patients.
引用
收藏
页码:1128 / 1138
页数:11
相关论文
共 89 条
[1]   Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products [J].
Anderson, Gail D. ;
Chan, Lingtak-Neander .
CLINICAL PHARMACOKINETICS, 2016, 55 (11) :1353-1368
[2]  
[Anonymous], 2006, The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General
[3]  
[Anonymous], Cardiovascular Diseases
[4]   Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial [J].
Anthenelli, Robert M. ;
Benowitz, Neal L. ;
West, Robert ;
St Aubin, Lisa ;
McRae, Thomas ;
Lawrence, David ;
Ascher, John ;
Russ, Cristina ;
Krishen, Alok ;
Evins, A. Eden .
LANCET, 2016, 387 (10037) :2507-2520
[5]   Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction [J].
Arefalk, Gabriel ;
Hambraeus, Kristina ;
Lind, Lars ;
Michaelsson, Karl ;
Lindahl, Bertil ;
Sundstrom, Johan .
CIRCULATION, 2014, 130 (04) :325-U90
[6]   Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts [J].
Arefalk, Gabriel ;
Hergens, Maria-Pia ;
Ingelsson, Erik ;
Arnlov, Johan ;
Michaelsson, Karl ;
Lind, Lars ;
Ye, Weimin ;
Nyren, Olof ;
Lambe, Mats ;
Sundstrom, Johan .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2012, 19 (05) :1120-1127
[7]  
Arnett DK, 2019, CIRCULATION, V140, pE563, DOI [10.1016/j.jacc.2019.03.010, 10.1161/CIR.0000000000000678, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.009]
[8]   EFFECT OF CIGARETTE-SMOKING AND BREATHING CARBON-MONOXIDE ON CARDIOVASCULAR HEMODYNAMICS IN ANGINAL PATIENTS [J].
ARONOW, WS ;
CASSIDY, J ;
VANGROW, JS ;
MARCH, H ;
KERN, JC ;
GOLDSMIT.JR ;
KHEMKA, M ;
PAGANO, J ;
VAWTER, M .
CIRCULATION, 1974, 50 (02) :340-347
[9]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[10]   Psychosocial interventions for smoking cessation in patients with coronary heart disease [J].
Barth, Juergen ;
Jacob, Tiffany ;
Daha, Ioana ;
Critchley, Julia A. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (07)